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Abstract Cell adhesion of osteoblasts and osteoclastic precur-
sors of hematopoietic origin is a prerequisite for osteoclast mat-
uration. We have investigated the relevance of osteoblast^ma-
trix binding and regulation of adhesion molecules to this
process. Human osteoblastic cells highly expressed CD44, a
major receptor for hyaluronan present in the surrounding bone
matrix. Crosslinking of CD44 on osteoblastic cells with speci¢c
antibodies augmented the expression of intercellular adhesion
molecule (ICAM)-1 and vascular cell adhesion molecule
(VCAM)-1. Hyaluronan, the major ligand of CD44, also up-
regulated ICAM-1 expression. Stimulation of CD44 on osteo-
blastic cells ampli¢ed their adhesion to monocytic cells through
ICAM-1 and VCAM-1. These results suggest that such cross-
talk among distinct adhesion molecules may be relevant to bone
metabolism, including osteoclastogenesis.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Osteoblast ; Osteoclast ; CD44; Hyaluronan;
Intercellular adhesion molecule-1;
Vascular cell adhesion molecule-1
1. Introduction
The de¢nition of the molecular basis of cell adhesion and its
importance in cell^cell and matrix interactions has progressed
during the last decade. Adhesion molecules like integrins
(LFA-1, VLA-4), the immunoglobulin superfamily (intercellu-
lar and vascular cell adhesion molecules (ICAM-1, VCAM-1),
and CD44 play major roles in cell^cell, cell^ECM (extracellu-
lar matrix) adhesion. Recent reports demonstrate that certain
adhesion molecules play a role as ‘signal transmitting mole-
cules’ as well as their adhesive function. We have previously
reported that ICAM-1 on rheumatoid synoviocytes induces
cytokine gene transcription via nuclear factor activation and
that stimulation of L1 integrin down-regulates ICAM-1 of
lung cancer cells through focal adhesion kinase [1,2].
CD44, known as a receptor for hyaluronan, is one of the
adhesion molecules that are involved in signal transmission
and regulating cellular function. Stimulation of CD44 with
monoclonal antibodies (mAbs) or hyaluronan activates T
cells, or induces cytokine or chemokine release from mono-
cytes [3,4]. We have previously reported the up-regulation of
VCAM-1, Fas and production of interleukin-6 after CD44
stimulation by hyaluronan on rheumatoid arthritis (RA)
synovial cells. Stimulation of CD44 on RA synovial cells aug-
mented their adhesion to T cells via the VCAM-1/VLA-4
pathway. [5^7]. These insights have prompted us to investigate
whether CD44 is ubiquitously involved in signal transmission,
and CD44^ECM adhesion plays an important role in regulat-
ing the expression of other adhesion molecules, such as
ICAM-1 and VCAM-1. Osteoblasts are one of the candidates
for these investigations as osteoblasts are surrounded by bone
matrix including hyaluronan, and adhesion of osteoblasts to
osteoclastic cells through the ICAM-1, VCAM-1 pathway is
crucial for osteoclastogenesis [8]. In addition, the precise role
of CD44 on osteoblasts largely remains unknown.
We here document that CD44-mediated signaling on osteo-
blastic cells induces the expression of ICAM-1 and VCAM-1,
leading to augmented adhesion of osteoblastic cells to the
monocytic cell line U937 mediated by these molecules. We
propose a new regulatory mechanism for bone metabolism
regulated by CD44^ECM interaction.
2. Materials and methods
2.1. Preparation of human osteoblastic cells
Osteoblast-like cells were puri¢ed from metaphyseal trabecular
bone in the proximal femur of four osteoarthritis patients during total
hip arthroplasty by the established procedures of Beresford et al. [9].
Brie£y, after removing pieces of cortical bone, articular cartilage, and
soft connective tissue, the fragments were cut into small pieces and
washed extensively. The bone explants were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM, Gibco, Grand Island, NY, USA)
containing 10% fetal calf serum (FCS, Gibco) in tissue culture plates.
When cell monolayers were con£uent after 6^8-week culture, the ex-
plants were removed and the cells were replated and incubated, which
resulted in new cellular outgrowth and eventually a con£uent mono-
layer of cells which possessed characteristics of the osteoblastic phe-
notype. Cells were used at the third to seventh passage.
2.2. Cell culture
The human monocytic lymphoma cell line U937 was obtained from
the American Type Culture Collection (ATCC, Rockville, MD, USA).
The cell lines were grown in DMEM with 10% heat-inactivated FCS.
2.3. Reagents and mAbs
Fragmented and native hyaluronan were kindly donated by the
Tokyo Research Institute of Seikagaku Co. The following mAbs
were used as puri¢ed immunoglobulin (Ig): major histocompatibility
class (MHC) class I mAb W6/32, anti-glycophorin mAb 10F7, CD11a
(LFA-1K) mAb TS1/22 (ATCC), control mAb Thy1.2, CD106
(VCAM-1) mAb (Becton Dickinson, San Jose, CA, USA), CD44
blocking mAb BU75 (Ancell, Bayport, MN, USA), CD44 mAb
NIH44-1, CD54 (ICAM-1) mAb 84H10, CD49d (VLA-4) mAb
NIH49d-1 (gifts from Dr. S. Shaw, Bethesda, MD, USA), and
CD106 mAb 2G7 (gift from Dr. W. Newman, Rockville, MD, USA).
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2.4. Stimulation of CD44
Cells were cultured until subcon£uence and then incubated with
NIH44-1 mAb (10 Wg/ml) for 30 min at 37‡C. After washing the cells
three times, 1 Wg/ml of goat anti-mouse IgG-Fc was added as the
second Ab for CD44 crosslinking. The cells were also incubated
with fragmented or native hyaluronan (0.1 Wg/ml) for 6 h at 37‡C.
2.5. Flow micro£uorometry
Staining and £ow cytometric analysis of osteoblastic cells were car-
ried out by standard procedures as already described using a FACS-
can (Becton Dickinson, Mountain View, CA, USA). Brie£y, cells
(2U105) were incubated with speci¢c mAbs and subsequently £uores-
cein isothiocyanate (FITC)-conjugated anti-goat IgG Ab, or incuba-
ted with phycoerythrin (PE)-conjugated CD54 (ICAM-1) mAb or
FITC-conjugated CD106 (VCAM-1) mAb at saturating concentra-
tions in FACS medium consisting of Hanks’ balanced salt solution
(Nissui, Tokyo, Japan), 0.5% human serum albumin (Yoshitomi, Osa-
ka, Japan), and 0.2% NaN3 (Sigma Aldrich) for 30 min at 4‡C. After
three washes in FACS medium, the cells were analyzed with FACS-
can. Ampli¢cation of the mAb binding was provided by a three-de-
cade logarithmic ampli¢er. Quanti¢cation of the cell surface antigens
on one cell was performed using beads, QIFKIT (Dako Japan, Kyoto,
Japan).
2.6. Adhesion assay
The adhesion assay was performed as previously described [8,10,11].
Brie£y, osteoblastic cells were applied to 24-well culture plates (Nunc,
Roskilde, Denmark) and cultured in DMEM with 10% heat-inacti-
vated FCS. U937 cells were labeled with sodium 51chromate (Dupont
NEN). 1U106 U937 cells in 1 mM phorbol myristate acetate (PMA,
Sigma Aldrich) in the presence or absence of relevant blocking mAb
(10 Wg/ml) were added and the cells incubated at 37‡C for 30 min in
phosphate-bu¡ered saline with 0.5% human serum albumin: non-ad-
herent cells were washed o¡ completely. Well contents were lysed with
1% Triton X-100 (Sigma Aldrich), and Q-emissions of adherent wells
were determined.
2.7. Statistical analysis
Signi¢cant di¡erences among groups within each experiment were
determined by ANOVA, followed by post-hoc Sche¡e’s F-test.
3. Results
3.1. Human osteoblastic cells highly express CD44, ICAM-1
First, we assessed the cell surface adhesion molecules on
puri¢ed human osteoblastic cells using FITC- or PE-conju-
gated mAbs by FACScan. A high level of CD44 expression,
a major receptor for hyaluronan, was detected on basal osteo-
blastic cells (Fig. 1). About half of the osteoblastic cells spon-
taneously expressed ICAM-1 without stimulation. However,
unlike CD44 or ICAM-1, the basal expression of VCAM-1
was almost negative on osteoblastic cells without stimulation.
These results demonstrate that osteoblastic cells express adhe-
sion molecules like CD44 and ICAM-1 in a stimulation-inde-
pendent manner.
3.2. CD44 crosslinking up-regulates ICAM-1 and VCAM-1
expression on osteoblastic cells
To characterize the function of CD44, we crosslinked cell
surface CD44 molecules on osteoblastic cells using a speci¢c
anti-CD44 mAb and a second crosslinker Ab. The surface
expression of ICAM-1 and VCAM-1 was measured by FACS-
can. After CD44 crosslinking on osteoblastic cells, we ob-
served a strong up-regulation of ICAM-1 (Fig. 1B,C).
VCAM-1 was also up-regulated after CD44 stimulation with
a speci¢c mAb (Fig. 1D,E). Next, we quantitated the change
of expression level of ICAM-1 and VCAM-1 after CD44 stim-
ulation using FACScan and QIFKIT standard beads. As
shown in Fig. 2, ICAM-1 was up-regulated two- to four-
fold after CD44 crosslinking, but not by crosslinking with
control anti-MHC class I mAb. VCAM-1 was almost negative
on basal osteoblastic cells, however, 8^20-fold up-regulation
of VCAM-1 molecules was observed after CD44 crosslinking.
Though the alteration of ICAM-1 molecules after CD44
Fig. 1. Phenotypic analysis and up-regulation of ICAM-1 and VCAM-1 by CD44 crosslinking on osteoblastic cells. Bone samples were ob-
tained from four osteoarthritis patients during total hip arthroplasty and osteoblastic cells were isolated. Puri¢ed human osteoblastic cells were
stained with CD44 mAb NIH44-1 (A), ICAM-1 mAb 84H10 (B,C), VCAM-1 mAb 2G7 (D,E). Osteoblastic cells were incubated in medium
(B,D) or crosslinked with anti-CD44 mAb NIH44-1 (C,E) at a concentration of 10 Wg/ml for 6 h. Flow cytometric analyses of ICAM-1 and
VCAM-1 expression were performed using FACScan. Histograms are representative data from four di¡erent donors.
FEBS 27068 12-3-03
Y. Fujii et al./FEBS Letters 539 (2003) 45^5046
Fig. 2. Quanti¢cation of ICAM-1 and VCAM-1 increased by CD44 crosslinking on osteoblastic cells. Puri¢ed human osteoblastic cells were
crosslinked with anti-CD44 mAb NIH44-1 or control anti-MHC class I mAb W6/32 at a concentration of 10 Wg/ml for 6 h and the expression
of ICAM-1 (A) and VCAM-1 (B) was analyzed by FACScan. Cell surface molecules on a single cell were quanti¢ed by standard beads
QIFKIT, after stimulation with control medium (open bars), anti-CD44 mAb (solid bars) or anti-MHC class I (hatched bars). Shown are rep-
resentative data of three di¡erent experiments from four di¡erent donors (designated OB1 to 4).
Fig. 3. Kinetic study of ICAM-1 and VCAM-1 up-regulation after CD44 stimulation. Human osteoblastic cells were stimulated with 10 Wg/ml
of anti-CD44 mAb for the indicated duration. The expression of ICAM-1 and VCAM-1 was analyzed by FACScan. Shown is the quanti¢ca-
tion of the cell surface antigens on a single cell, calculated by QIFKIT, of representative data among four di¡erent experiments. *P6 0.05 com-
pared with control.
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crosslinking was smaller than that of VCAM-1, ICAM-1 ex-
ceeded VCAM-1 by 5^10-fold in the total number of mole-
cules expressed on the osteoblastic cell surface.
Time course experiments showed that ICAM-1 expression
on osteoblasts reached maximum levels (approximately a
four-fold increase compared to unstimulated cells) in 8 h after
CD44 crosslinking, lasting until 24 h of incubation (Fig. 3A).
VCAM-1 was markedly up-regulated in 4 h, reaching its max-
imum level in 8 h after CD44 crosslinking (Fig. 3B). Compar-
ing the induction pattern of these two molecules, VCAM-1
had a tendency to decrease more rapidly than ICAM-1. These
results demonstrate that CD44 is a potent inducer of ICAM-1
and VCAM-1 expression on osteoblastic cells.
3.3. Hyaluronan up-regulates ICAM-1 and VCAM-1 on
osteoblasts
Hyaluronan is known as a major ligand for cell surface
CD44. We assessed the biological activity of hyaluronan in
ICAM-1 and VCAM-1 expression on osteoblastic cells. Stim-
ulation of CD44 with hyaluronan e⁄ciently up-regulated
ICAM-1 on osteoblastic cells (Fig. 4A). In addition, various
lengths of hyaluronan fragments were tested for ICAM-1 up-
regulation, as the di¡erent sizes of hyaluronan are reported to
possess di¡erent biological e¡ects. Di¡erent lengths of hyalur-
onan, including native hyaluronan, a 40-kDa fragment and a
6.9-kDa fragment, up-regulated ICAM-1 expression. Among
them, the fragmented 6.9-kDa hyaluronan most e¡ectively
augmented ICAM-1 expression (Fig. 4A). To demonstrate
the direct interaction of hyaluronan and CD44, we stimulated
osteoblasts in the presence and absence of the anti-CD44
blocking Ab BU75. As shown in Fig. 4B, up-regulation of
ICAM-1 induced by fragmented hyaluronan was inhibited
by the anti-CD44 mAb. Hyaluronan also augmented
VCAM-1 expression, however, this increase was not blocked
by mAb BU75 (data not shown). These results indicate that
hyaluronan, especially certain fragmented types, appears to be
an inducer of ICAM-1 on osteoblastic cells through binding
to CD44.
3.4. CD44 stimulation augments adhesion of osteoblasts to
monocytic cells through up-regulation of
ICAM-1/VCAM-1
We investigated whether CD44-induced ICAM-1 and
VCAM-1 up-regulation of osteoblastic cells augments their
adhesion to the monocytic cell line U937 [12,13]. 10^15% of
PMA-pretreated U937 cells bound non-stimulated osteoblas-
tic cells (Fig. 5A). Engagement with control mAb W6/32 did
not induce their adhesion and the adhesion was scarcely de-
creased by the addition of anti-LFA-1 mAb (data not shown).
However, a two- to ¢ve-fold increase of this binding was
observed after crosslinking of CD44 on osteoblastic cells
with a speci¢c mAb (Fig. 5A). This increased binding was
signi¢cantly inhibited in the presence of anti-VLA-4 mAb,
and especially by LFA-1 mAb. Also, a binding assay was
performed by stimulating osteoblastic cells with a 6.9-kDa
fragment of hyaluronan. As shown in Fig. 5B, fragmented
hyaluronan e⁄ciently augmented the binding of osteoblastic
cells to PMA-pretreated U937 cells, and the binding was in-
hibited in the presence of anti-VLA-4 mAb or anti-LFA-1
mAb.
Fig. 4. Upregulation of ICAM-1 on osteoblasts by hyaluronan. Osteoblastic cells were incubated with 100 ng/ml of fragmented (6.9 kDa and
40 kDa) or full-length hyaluronan for 6 h (A). Osteoblastic cells were stimulated with fragmented 6.9-kDa hyaluronan in the presence or ab-
sence of the anti-CD44 mAb BU75 (B). Expression of ICAM-1 was analyzed by FACScan. After quanti¢cation of the cell surface antigens on
a single cell, calculated by QIFKIT, the ratio to the quantity of ICAM-1 on unstimulated cells was obtained, among four di¡erent experiments.
Data are presented as meanUS.D. *P6 0.05 compared with control.
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These results demonstrate that CD44 plays an important
role in increasing the binding of osteoblastic cells/monocytic
cells by up-regulation of adhesion molecules, especially
ICAM-1. Augmentation of the adhesion by hyaluronan stim-
ulation suggests that hyaluronan, especially fragmented types,
is a biologically important stimulator for CD44, and that
might be increasing osteoblast/monocyte binding through
the LFA-1/ICAM-1 pathway.
4. Discussion
Adhesion molecules are involved in signaling in two reverse
directions in cell^cell and cell^matrix interactions. We here
propose that stimulation of the adhesion molecule CD44 per
se plays a pivotal role in the ampli¢cation of particular adhe-
sion molecules, ICAM-1 and VCAM-1 expression. We deduce
this from the following novel ¢ndings: (1) CD44 crosslinking
on osteoblastic cells up-regulated ICAM-1 and VCAM-1 ex-
pression; (2) hyaluronan, the ligand of CD44, also e¡ectively
increased ICAM-1, and (3) integrin-dependent adhesion of
osteoblastic cells to U937 was markedly increased by stimu-
lating CD44 on osteoblastic cells.
CD44 is a 90-kDa transmembrane glycoprotein widely dis-
tributed on the surface of most leukocytes, ¢broblasts, kera-
tinocytes, epithelial cells, and osteoblastic cells [14,15]. Our
present report strengthens the important role of CD44 as a
signal-transmitting molecule, and further suggests the concept
that CD44^ECM interaction is ubiquitously playing a pivotal
role for regulating the expression of adhesion molecules.
The best known ligand for CD44 is hyaluronan. Hyalur-
onan is a major extracellular glycosaminoglycan, found in al-
most all types of ECMs including bone matrix. Several studies
have suggested diverse biological activities of hyaluronan de-
pending on its molecular mass. High molecular mass hyalur-
onan inhibits cellular proliferation of endothelial cells, ¢bro-
blasts, and mitogen-stimulated lymphocytes, whereas low
molecular mass fragments have stimulatory e¡ects on angio-
genesis and cytokine production [3,4,16^20].
We have previously reported that stimulation of RA syno-
vial cells with 6.9-kDa hyaluronan up-regulated VCAM-1,
whereas in the present study, the same stimulus up-regulated
dominantly ICAM-1 on osteoblastic cells [5]. 6.9-kDa hyalur-
onan up-regulated Fas on RA synovial cells, while down-reg-
ulation of Fas was observed by the same stimulus on a lung
cancer cell line [21]. These results suggest that the same mo-
lecular mass of hyaluronan can exert di¡erent biological ef-
fects depending on cell type, and further investigation is re-
quired to clarify the underlying mechanism.
The structural material of bone is a composite of organic
and inorganic phases. The organic bone matrix component is
made of collagen and non-collagenous proteins, such as os-
teocalcin, osteonectin, proteoglycans, and hyaluronan, which
are synthesized by osteoblasts and osteoclasts [22^24]. Hya-
luronan is known to localize around the CD44-positive osteo-
blasts [25], however, the fragmented hyaluronan more po-
tently up-regulated ICAM-1 than full-length hyaluronan.
These results suggest that ICAM-1 on osteoblasts is up-regu-
lated when fragmented hyaluronan, but not full-length hya-
luronan, is produced nearby. Metastasis of malignant cells to
bone might be one of the cases that fragmented hyaluronan is
enriched around CD44-positive osteoblasts. Tumor metastasis
to bone is known to facilitate bone resorption. In the case of
breast cancer, signi¢cant increases of hyaluronidase levels,
considered to be derived from tumor cells, are observed in
metastatic sites compared to the primary tumor [26]. These
results suggest that locally produced fragmented hyaluronan
may stimulate CD44 on osteoblasts, and facilitate the binding
of osteoblast/osteoclast precursor cells via up-regulated
ICAM-1, leading to facilitation of osteoclastogenesis and
bone resorption.
Based on the ¢ndings presented here, we propose that
CD44 is a ubiquitously regulating cellular function, i.e. we
observed that stimulation of CD44 by crosslinking or ligation
with hyaluronan induces up-regulation of ICAM-1 and
VCAM-1 on osteoblastic cells. These interactions of CD44
and hyaluronan may play a pivotal role in bone metabolism,
including osteoclastogenesis.
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